These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 2175584)
1. [Modeling of the relation between plasma concentration of the active metabolite of perindopril and inhibition of the activity of plasma converting enzyme in healthy volunteers]. Bellissant E; Chau NP; Thuillez C; Giudicelli JF Arch Mal Coeur Vaiss; 1990 Jul; 83(8):1285-9. PubMed ID: 2175584 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients. Bellissant E; Giudicelli JF Br J Clin Pharmacol; 2001 Jul; 52(1):25-33. PubMed ID: 11453887 [TBL] [Abstract][Full Text] [Related]
3. Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. Verpooten GA; Genissel PM; Thomas JR; De Broe ME Br J Clin Pharmacol; 1991 Aug; 32(2):187-92. PubMed ID: 1657092 [TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure. Sennesael J; Ali A; Sweny P; Vandenburg M; Slovic D; Dratwa M; Resplandy G; Genissel P; Desche P Br J Clin Pharmacol; 1992 Jan; 33(1):93-9. PubMed ID: 1311597 [TBL] [Abstract][Full Text] [Related]
5. Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects. Louis WJ; Workman BS; Conway EL; Worland P; Rowley K; Drummer O; McNeil JJ; Harris G; Jarrott B J Cardiovasc Pharmacol; 1992 Sep; 20(3):505-11. PubMed ID: 1279299 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the pharmacokinetics and pharmacodynamics of oral doses of perindopril in normotensive Chinese and Caucasian volunteers. Anderson PJ; Critchley JA; Tomlinson B; Resplandy G Br J Clin Pharmacol; 1995 Apr; 39(4):361-8. PubMed ID: 7640141 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the pharmacokinetics and pharmacodynamics of perindopril, cilazapril and enalapril. Louis WJ; Conway EL; Krum H; Workman B; Drummer OH; Lam W; Phillips P; Howes LG; Jackson B Clin Exp Pharmacol Physiol Suppl; 1992; 19():55-60. PubMed ID: 1327596 [TBL] [Abstract][Full Text] [Related]
8. Effects of perindopril on angiotensin converting enzyme in tissues of the rat. Jackson B; Cubela RB; Johnston CI J Hypertens Suppl; 1988 Dec; 6(3):S51-4. PubMed ID: 2852236 [TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics and pharmacodynamics of perindopril in patients with hepatic cirrhosis. Tsai HH; Lees KR; Howden CW; Reid JL Br J Clin Pharmacol; 1989 Jul; 28(1):53-9. PubMed ID: 2550045 [TBL] [Abstract][Full Text] [Related]
11. First LC-MS/MS electrospray ionization validated method for the quantification of perindopril and its metabolite perindoprilat in human plasma and its application to bioequivalence study. Jain DS; Subbaiah G; Sanyal M; Pande UC; Shrivastav P J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jun; 837(1-2):92-100. PubMed ID: 16709467 [TBL] [Abstract][Full Text] [Related]
12. Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. Lecocq B; Funck-Brentano C; Lecocq V; Ferry A; Gardin ME; Devissaguet M; Jaillon P Clin Pharmacol Ther; 1990 Mar; 47(3):397-402. PubMed ID: 2311339 [TBL] [Abstract][Full Text] [Related]
13. Experience with perindopril in normal volunteers. Waeber B; Nussberger J; Perret L; Santoni JP; Brunner HR Arch Mal Coeur Vaiss; 1989 May; 82 Spec No 1():35-41. PubMed ID: 2549899 [TBL] [Abstract][Full Text] [Related]
14. Bioequivalence study of two perindopril erbumine tablet formulations in healthy volunteers. Setiawati E; Deniati SH; Yunaidi DA; Handayani LR; Santoso ID; Arland JA; Setiawati A; Lian LY Arzneimittelforschung; 2011; 61(4):234-8. PubMed ID: 21650082 [TBL] [Abstract][Full Text] [Related]
16. Perindopril. A review of its pharmacokinetics and clinical pharmacology. Macfadyen RJ; Lees KR; Reid JL Drugs; 1990; 39 Suppl 1():49-63. PubMed ID: 2407493 [TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state. Parker E; Aarons L; Rowland M; Resplandy G Eur J Pharm Sci; 2005 Sep; 26(1):104-13. PubMed ID: 15982858 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of RU44403, an active form of newly developed angiotensin-converting enzyme inhibitor (RU44570) in the rat. Hirayama M; Kurihara A; Manabe T; Hasegawa Y Drug Metab Dispos; 1994; 22(4):601-6. PubMed ID: 7956736 [TBL] [Abstract][Full Text] [Related]
20. Perindopril treatment prevents the loss of endothelial nitric oxide function and development of neo-intima in rabbits. Hickey H; Makdissi M; Hyland R; Wilks D; Dusting GJ J Mol Cell Cardiol; 1996 Sep; 28(9):1985-94. PubMed ID: 8899557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]